Regenerative Medicine Market to Reach $30,237 Million, Globally, by 2022 - Allied Market Research

PORTLAND, Oregon, August 31, 2016 /PRNewswire/ --

A new report published by Allied Market Research titled, "Regenerative Medicine Market- Global Opportunity Analysis and Industry Forecast, 2014 - 2022", projects that the global regenerative medicine market would reach $30,237 million by 2022. Cell therapy segment is expected to dominate the market throughout the forecast period. North America led the global market in 2015, and is expected to remain dominant during the 2015-2022.

     (Logo: http://photos.prnewswire.com/prnh/20140911/647229 )

Major factors boosting the market growth include technological advancements in tissue & organ regeneration, increase in prevalence of chronic diseases & trauma emergencies, prominent potential of nanotechnology, and emergence of stem cell technology. In addition, increase in incidence of degenerative diseases and limited availability of organs for transplants are expected to boost the market growth. The ability of regenerative medicine to replace, repair, and regenerate damaged tissues & organs stimulated the market growth.

The utilization of nano-materials in wound care, drug delivery, and immunomodulation would create new growth opportunities for the market. However, stringent regulations, operational inefficiency, lack of awareness about tissue engineering & regenerative medicine-based products and high cost restricts its growth. An analyst at Allied Market Research states, Advancements in stem cell technology and growing demand of regenerative medicine in the emerging economies would fuel the market growth. In addition, the developed nations are adopting technological advancements in tissue engineering and regenerative medicine field at a rapid pace, which is expected to aid market expansion worldwide.

Sample of the Regenerative Medicine Market Report can be accessed on the website at https://www.alliedmarketresearch.com/regenerative-medicines-market

The cell therapy segment accounted for over three-fifths of the overall regenerative medicine market in 2015. This was due to the wide adoption of cell therapy for the treatment of several diseases such as musculoskeletal, cardiovascular, oncology, wound healing, and others. Small molecules & biologics has emerged as the fastest growing segment and is projected to register a CAGR of 34.2% during the forecast period. This is due to biologics, which is a classic active substance, delivering a better overall economic return. These molecules have revolutionized the treatment of specific diseases such as cancer, musculoskeletal diseases, rheumatoid arthritis, and non-healing wounds.

Biologically derived materials, such as collagen and xenogeneic, are majorly applicable in the construction of protein membranes in connective tissues, surgical procedures for valvular diseases, liver tissue engineering, construction of biopolymer scaffolds for tissue engineering, and others. The growing demand for these biologically derived materials further boosts the market growth. The biologically derived material segment accounted for the major share in 2015, whereas, the synthetic material is expected to grow at a significant CAGR of 35.5% during the forecast period.

Musculoskeletal and wound healing application together accounted for over 60% share of the total market in 2015. Cell therapies are mostly utilized for the treatment of musculoskeletal diseases such as a bone tissue replacement, cartilage, and tendon and ligament repair & replacement. In addition, osteoporosis is one of the most prevalent disease that requires tissue engineering, and more than 75 million people suffer from osteoporosis in Europe, U.S., and Japan; thus increasing the demand for regenerative medicine.

Geographically, North America accounted for the majority of the market share in 2015, and is expected to maintain its lead throughout. This is attributed to the presence of higher capital investment, high disposable income of patients (increasing the buying potential), rise in clinical studies, and favorable government policies for the commercialization of tissue engineering and regenerative medicine products. However, Asia-Pacific is projected to be the fastest growing region, owing to the improving healthcare infrastructure and healthcare expenditures in the emerging markets (such as India and China) to overcome the unmet medical needs. In addition, tissue engineering and regenerative medicine market is growing substantially due to the increasing incidence of accidental trauma injuries in this region. Increasing incidences of injuries and the ageing population also contributes to the market growth.

Key findings of Regenerative Medicines Market:

• Biologically derived materials led the market, accounting for almost four-sevenths of the overall market revenue in 2015, and is projected to grow at a CAGR of 31.6% during the forecast period.
• Scaffold in synthetic material segment is expected to grow at a CAGR of 42.4%, owing to the degradation properties and bioabsorbable polymer, which acts as a bone fixation device.
• U.S. is projected to maintain its lead in the regenerative medicine market until 2022.
• Musculoskeletal and wound healing applications together accounted for around 60% of the overall market shares in 2015.
• China and Japan are the major shareholders, jointly accounting for almost two-thirds in the Asia-Pacific market.
• The collagen segment constitutes a major share of the biologically derived materials market.
• Three-dimensional polymer technology is anticipated to grow at fastest rate, with a CAGR of 44% from 2016 to 2022.

Key players in the regenerative medicine market are highly focused on expanding their business operations in the emerging countries with new product launches as a preferred strategy. Leading players profiled in the report include Stryker Corporation, Zimmer Biomet Holdings, Inc., Medtronic plc, Baxter International Inc., DePuy Synthes, Organogenesis Inc. (Advanced Biohealing), Integra Lifesciences Holdings Corporation, Acelity Holdings, Inc., Ocata Therapeutics Inc. (Astellas Pharma Inc.), and CryoLife Inc.

Similar Reports Published by Allied Market Research -

Oncology/Cancer Drugs Market - https://www.alliedmarketresearch.com/oncology-cancer-drugs-market

Biosimilars Market - https://www.alliedmarketresearch.com/global-biosimilars-market

About Us:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions". AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:
Dhananjay Potle
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Int'l: +1-503-894-6022
Toll Free: +1-800-792-5285 (U.S. & Canada)
E-mail: sales@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

SOURCE Allied Market Research